Concurrent Investment Advisors LLC Acquires New Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Concurrent Investment Advisors LLC purchased a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,203 shares of the company's stock, valued at approximately $361,000.

A number of other institutional investors have also added to or reduced their stakes in PBH. CIBC Private Wealth Group LLC grew its stake in shares of Prestige Consumer Healthcare by 48.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after purchasing an additional 152 shares during the last quarter. Opal Wealth Advisors LLC purchased a new position in shares of Prestige Consumer Healthcare during the first quarter valued at approximately $38,000. Headlands Technologies LLC purchased a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $40,000. McIlrath & Eck LLC lifted its holdings in shares of Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock valued at $75,000 after purchasing an additional 154 shares during the last quarter. Finally, Johnson Financial Group Inc. purchased a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $93,000. Institutional investors own 99.95% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Royal Bank Of Canada raised shares of Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $93.33.

Prestige Consumer Healthcare Price Performance

PBH traded down $1.32 during trading on Tuesday, reaching $75.10. The company's stock had a trading volume of 259,146 shares, compared to its average volume of 313,301. The company has a market cap of $3.71 billion, a price-to-earnings ratio of 17.51, a PEG ratio of 2.30 and a beta of 0.43. The company has a quick ratio of 2.82, a current ratio of 4.20 and a debt-to-equity ratio of 0.55. The firm has a fifty day simple moving average of $83.63 and a two-hundred day simple moving average of $82.39. Prestige Consumer Healthcare Inc. has a 1 year low of $64.94 and a 1 year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a net margin of 18.86% and a return on equity of 12.87%. The firm had revenue of $296.52 million for the quarter, compared to analyst estimates of $289.36 million. During the same period last year, the business earned $1.02 EPS. Prestige Consumer Healthcare's revenue for the quarter was up 7.0% compared to the same quarter last year. As a group, analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.